Review Papers Claim by Claim

Concise evidence synthesis (claims tied to the paper)

• Localization: Insulin‑immunoreactivity was localized to median neurosecretory cells (MNCs) in the protocerebrum, with axons to corpora cardiaca/allata and additional labelled cells in the suboesophageal ganglion — described and diagrammed in the paper (Fig.1–3) Localization of ILP in T. molitor
• Temporal pattern: The MNCs show cyclical changes: minimal staining at larval→pupal ecdysis (day 0), accumulation on days 1–2 (peak), marked loss of staining on day 3 with increased staining in axon termini and haemolymph, then recovery by adult emergence — this temporal release pattern is central to the paper's functional claim Temporal ILP release pattern
• Haemolymph molecule size: Western blot of pooled day‑3 haemolymph showed a single insulin‑reactive band at ~6.5 kDa — consistent with an insulin‑family peptide rather than the larger (~30 kDa) PTTH described in some Lepidoptera 6.5 kDa ILP band in haemolymph
• Functional test: Injection of anti‑insulin serum at times corresponding to observed releases (immediately after ecdysis and around day 3) significantly delayed pupal→adult ecdysis, whereas control serum did not — supporting causal role of ILP in timing of ecdysis Anti-insulin delays ecdysis

Critical appraisal — strengths, limitations, and blindspots

1. Strengths
   • Multimodal evidence: immunohistochemistry + RIA + immunoblot + functional perturbation (antiserum injections) converge on the same developmental windows — increases internal consistency and causal inference Convergent evidence in study
2. Limitations & caveats
   • Antibody specificity: the authors used anti‑bovine insulin serum (raised against vertebrate insulin). Cross‑reactivity can detect insulin‑family peptides but cannot define primary sequence; without peptide sequencing or molecular cloning, identity remains presumptive (insulin‑like) rather than definitive (exact sequence unknown) Antibody specificity limitation
   • Quantitation: RIA brain data are presented as means (3–5 determinations) and immunohistochemistry relied on semi‑quantitative staining scores by observers — good for pattern detection but limited for precise kinetics or concentration–response relationships.
   • Molecular resolution: the 6.5 kDa band is consistent with insect ILPs (e.g., bombyxins ≈5 kDa) but authors did not provide amino‑acid sequencing, mass spectrometry, or molecular cloning. Modern validation (peptide MS, genomic/transcriptomic match) is needed to confirm the peptide identity and gene locus.
   • Physiological specificity: anti‑insulin injections delay ecdysis, but antibody blockade can have off‑target effects (immune complexes, Fc interactions). Complementary approaches (purified peptide rescue, RNAi of candidate ILP genes) would strengthen causal claims.
   • Generality across taxa: paper argues that this ILP functions as PTTH in T. molitor; however, PTTH is heterogeneous across insects (small insulin‑family PTTHs in some species, larger 30 kDa PTTHs in others). The functional equivalence should be interpreted with species specificity in mind and tested biochemically on isolated prothoracic tissue or via recombinant peptide bioassays.
3. Blindspots / missing experiments
   • Sequence identification (MS or cDNA cloning) of the 6.5 kDa molecule.
   • Receptor identification: demonstration that prothoracic tissues express an insulin receptor responsive to this ILP and that receptor activation stimulates ecdysteroid synthesis.
   • Purified peptide bioassays on isolated prothoracic glands or epidermal tissues to show direct prothoracicotropic activity (dose‑response, species specificity).

How robust is the authors' central claim?

The evidence the authors present is internally consistent and biologically plausible: insulin‑immunoreactivity localized to neurosecretory cells that project to the CA, temporal release coinciding with haemolymph appearance and ecdysis timing, and functional blockade delaying ecdysis together make a convincing case that an insulin‑like peptide participates in timing ecdysis in T. molitor. However, the claim that this peptide is the prothoracicotropic hormone (PTTH) is provisional because molecular identification and direct biochemical demonstration of prothoracic stimulation are lacking. Confidence: moderate (see citations below) Authors

What would falsify the conclusion?

• Identification (by MS/cDNA) of the 6.5 kDa peptide and demonstration that its recombinant form does not stimulate ecdysteroid production in target tissues would falsify functional identity.
• Showing that anti‑insulin serum delays ecdysis via non‑specific immune/inflammatory mechanisms (e.g., injecting Fc fragments or heat-inactivated serum controls with same effect) would weaken causal interpretation.

Concrete suggestions to advance the field (experiments)

1. Mass spectrometry sequencing of the 6.5 kDa band from day‑3 haemolymph; validate peptide mass and disulfide pairing typical of insulin family.
2. Clone and sequence candidate ILP cDNAs from T. molitor brain (use modern transcriptomics / RACE PCR) and compare to bombyxin / locust ILP families.
3. Recombinant expression of the candidate peptide and direct bioassay: incubate isolated prothoracic glands (or abdominal epidermal tissues claimed to produce ecdysteroids) with peptide and measure ecdysteroid release (HPLC/RIA) to demonstrate prothoracicotropic action.
4. RNAi (or CRISPR) knockdown of the candidate ILP gene(s) and measurement of developmental timing and ecdysteroid titres as an orthogonal test to antibody blockade.

Useful contextual citations

The authors situate their findings among work identifying bombyxins and other insect insulin‑family peptides; those studies show insect ILPs can be ~4–6 kDa and sometimes functionally prothoracicotropic in particular taxa — the proposal for T. molitor fits that literature but requires modern molecular confirmation Context: bombyxin and PTTH heterogeneity